Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is listed today as PDS Biotechnology Corporation: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2015 | $56 M | No. 3 | $50 to $250 million | equity | SEC | |
| Nov 2014 | $8 M | No. 2 | $2 to $10 million | equity | SEC | |
| Mar 2013 | $7 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Edge Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2015).
SEC Form D · Apr 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2015
That is all the official record says: Edge Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Edge Therapeutics, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Albert N. Marchio II | Person | not stated | not stated | Held Series C-1 preferred stock (Form 3, 2015) | SEC Form 3 |
| Andrew J. Einhorn | Person | not stated | not stated | Held Series B-1CONVERTIBLE, C and C-1 preferred stock (Form 3, 2015) | SEC Form 3 |
| Brian A. Leuthner | Person | not stated | not stated | Held Series C-2 preferred stock (Form 3, 2015) | SEC Form 3 |
| James J. Loughlin | Person | not stated | not stated | Held Series C-2 preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Kurt G. Conti | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2015) | SEC Form 3 |
| R. Loch Macdonald | Person | not stated | not stated | Held Series A and C-1 preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Robert J. Spiegel | Person | not stated | not stated | Held Series C-1 and C-2 preferred stock, director (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 104 investors.
Largest shareholders today
Institutions holding PDS Biotechnology Corporation shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$1 M2.98%
- Militia Capital Management LLC$1 M2.97%
- Susquehanna International Group, LLP$1 M1.41%
- Renaissance Technologies LLC$0 M1.11%
- Geode Capital Management, LLC$0 M1.10%
- BlackRock, Inc.$0 M1.07%
- Focus Partners Wealth$0 M0.99%
- Quantinno Capital Management LP$0 M0.99%
- Jane Street Group, LLC$0 M0.91%
- Vanguard Fiduciary Trust Co$0 M0.64%
- Blair William & Co/il$0 M0.54%
- Virtu Financial LLC$0 M0.50%
- Acadian Asset Management LLC$0 M0.43%
- UBS Group AG$0 M0.42%
- Inspirion Wealth Advisors, LLC$0 M0.34%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Albert N. Marchio II | Executive officer | Apr 2015 |
| Andrew Loch Einhorn | Executive officer | Apr 2015 |
| Brian A. Leuthner | Executive officer | Apr 2015 |
| Carl J. Soranno | Executive officer | Apr 2015 |
| Herbert J. Faleck | Executive officer | Apr 2015 |
| Robert Loch Macdonald | Executive officer | Apr 2015 |
| Priya Loch Jambhekar | Executive officer | Mar 2013 |
| Brian A. Leuthner | Director | Apr 2015 |
| Isaac J. Blech | Director | Apr 2015 |
| James J. Loughlin | Director | Apr 2015 |
| Kurt J. Conti | Director | Apr 2015 |
| Robert J. Spiegel | Director | Apr 2015 |
| Robert Loch Macdonald | Director | Apr 2015 |
| Sol J. Barer | Director | Apr 2015 |
| Isaac Loch Blech | Director | Mar 2013 |
| Brian A. Leuthner | Promoter | Mar 2013 |
| Carl J. Soranno | Promoter | Mar 2013 |
| Robert Loch Macdonald | Promoter | Mar 2013 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.